The FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.
PVX108 received FDA Fast Track designation in August 2026 as a synthetic T-cell epitope peptide therapy for peanut allergy—one of the first allergen immunotherapy programs built entirely on short peptides rather than whole extracts.
FDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.
Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.
The FDA Pharmacy Compounding Advisory Committee recommended six peptide bulk substances for 503A list consideration after two days of safety, sourcing, and dosing testimony in July 2026.
Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.
ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.
Peptide suppliers face new scorecard metrics on solvent recovery and waste intensity in 2026.
Focusing on green production: peptide factories and sustainable skincare development.
Empowering small and medium-sized beauty enterprises: how peptide factories support industry development.
Technology empowers quality upgrade in peptide factories.
Classic Matrixyl and Argireline peptides return to mass-market anti-wrinkle launches in 2026.